Watson Pharmaceuticals Income Statement
View: Annual | Quarterly
| Quarter Ending Sep 09 (Prelim.) |
Quarter Ending Jun 09 |
Quarter Ending Jun 09 |
Quarter Ending Mar 09 |
Quarter Ending Mar 09 |
|
|---|---|---|---|---|---|
| Revenue | 662.1 | 677.8 | 677.8 | 667.4 | 667.4 |
| Cost of Goods Sold | 353.7 | 393.1 | 393.1 | 388.7 | 388.7 |
| Gross Profit | 308.4 | 284.7 | 284.7 | 278.7 | 278.7 |
| Gross Profit Margin | 46.6% | 42.0% | 42.0% | 41.8% | 41.8% |
| SG&A Expense | 120.1 | 128.3 | 128.3 | 134.6 | 134.6 |
| Depreciation & Amortization | 22.2 | 22.1 | 22.1 | 21.8 | 21.8 |
| Operating Income | 111.3 | 95.2 | 95.2 | 84.7 | 84.7 |
| Operating Margin | 16.8% | 14.0% | 14.0% | 12.7% | 12.7% |
| Nonoperating Income | (0.4) | 2.4 | 2.4 | 1.2 | 1.2 |
| Nonoperating Expenses | (8.0) | (3.3) | (3.3) | (2.7) | (2.7) |
| Income Before Taxes | 102.3 | 90.6 | 90.6 | 80.0 | 80.0 |
| Income Taxes | 39.3 | 37.6 | 37.6 | 30.9 | 30.9 |
| Net Income After Taxes | 63.0 | 53.0 | 53.0 | 49.1 | 49.1 |
| Continuing Operations | 63.0 | 53.0 | 53.0 | 49.1 | 49.1 |
| Discontinued Operations | -- | -- | -- | -- | -- |
| Total Operations | 63.0 | 53.0 | 53.0 | 49.1 | 49.1 |
| Total Net Income | 63.0 | 53.0 | 53.0 | 49.1 | 49.1 |
| Net Profit Margin | 9.5% | 7.8% | 7.8% | 7.4% | 7.4% |
| Diluted EPS from Total Net Income ($) | 0.55 | 0.46 | 0.46 | 0.43 | 0.43 |
| Dividends per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
© 2009 Morningstar, Inc. Financial Data provided by
